ZYME: Zymeworks, Inc.
About
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Current Value
$14.671 Year Return
Current Value
$14.671 Year Return
Key Details
Market Cap
$1.03B
P/E Ratio
-9.8
1Y Stock Return
79.68%
1Y Revenue Growth
-86.52%
Dividend Yield
0.00%
Price to Book
2.8
Strategies that include ZYME
Stock's related to ZYME
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 46.36% | $2.09B | -9.52% | 0.00% |
| RCKT | 43.12% | $1.20B | -39.83% | 0.00% |
| ALEC | 41.83% | $377.04M | -19.46% | 0.00% |
| FOLD | 40.75% | $2.84B | -11.52% | 0.00% |
| KFRC | 39.87% | $1.10B | -8.71% | 0.66% |
| ABCL | 39.22% | $800.44M | -37.56% | 0.00% |
| ALLO | 38.37% | $444.50M | -24.82% | 0.00% |
| PGEN | 38.13% | $228.91M | -28.00% | 0.00% |
| APLS | 37.54% | $3.61B | -41.27% | 0.00% |
| PLRX | 37.00% | $778.32M | -9.55% | 0.00% |
| VRDN | 36.11% | $1.60B | +28.92% | 0.00% |
| EWCZ | 35.63% | $281.81M | -57.40% | 0.00% |
| ALT | 35.56% | $531.30M | +194.09% | 0.00% |
| XNCR | 35.48% | $1.65B | +27.73% | 0.00% |
| RICK | 35.43% | $440.11M | -13.68% | 0.51% |
| FARO | 35.25% | $486.17M | +40.51% | 0.00% |
| IOVA | 35.20% | $2.50B | +58.41% | 0.00% |
| MGTX | 35.09% | $467.36M | +9.12% | 0.00% |
| CNDT | 34.97% | $569.21M | +20.27% | 0.00% |
| ANAB | 34.95% | $607.66M | +40.93% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| QTTB | -0.01% | $354.34M | +188.64% | 0.00% |
| AGO | -0.02% | $4.66B | +37.77% | 1.01% |
| PAGP | 0.03% | $3.67B | +16.79% | 0.00% |
| MANU | 0.05% | $2.88B | -9.41% | 0.00% |
| DK | -0.09% | $1.14B | -34.04% | 5.64% |
| RYAN | -0.12% | $8.81B | +55.63% | 0.62% |
| HIHO | 0.17% | $8.63M | 0.00% | 6.12% |
| MNR | 0.17% | $1.66B | -10.71% | 15.90% |
| MUX | -0.17% | $458.33M | +14.70% | 0.00% |
| GIS | 0.22% | $34.85B | -2.91% | 3.78% |
| BYND | -0.24% | $318.19M | -22.91% | 0.00% |
| AZO | -0.32% | $52.52B | +16.10% | 0.00% |
| RILY | -0.32% | $145.72M | -79.86% | 20.75% |
| LFVN | 0.33% | $169.84M | +130.61% | 1.10% |
| TK | 0.34% | $728.26M | +11.06% | 0.00% |
| SAVA | -0.36% | $1.35B | +25.50% | 0.00% |
| TEN | -0.37% | $606.64M | +3.32% | 4.39% |
| FLXS | 0.37% | $301.86M | +215.00% | 1.02% |
| KLG | -0.39% | $1.48B | +45.15% | 3.71% |
| ASC | -0.39% | $517.16M | -7.62% | 8.45% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CAH | -15.29% | $28.64B | +12.14% | 1.70% |
| COR | -13.23% | $47.48B | +21.20% | 0.86% |
| MCK | -13.04% | $78.15B | +35.51% | 0.42% |
| STNG | -11.86% | $2.96B | +0.87% | 2.75% |
| IMRN | -10.79% | $10.31M | -5.04% | 0.00% |
| NGL | -9.73% | $572.94M | +5.60% | 0.00% |
| TCTM | -7.94% | $8.10M | -42.99% | 0.00% |
| PRPO | -7.84% | $9.10M | -13.65% | 0.00% |
| CHD | -7.35% | $27.18B | +19.50% | 1.03% |
| TTE | -7.13% | $138.45B | -11.95% | 5.50% |
| FLNG | -6.97% | $1.42B | -14.21% | 11.33% |
| NVGS | -6.83% | $1.12B | +8.76% | 1.24% |
| GAN | -6.79% | $83.39M | +21.19% | 0.00% |
| PULM | -6.47% | $19.83M | +202.98% | 0.00% |
| LMT | -6.28% | $126.40B | +18.99% | 2.36% |
| OXBR | -6.22% | $19.05M | +178.18% | 0.00% |
| E | -6.16% | $46.24B | -10.80% | 9.02% |
| ORLY | -5.67% | $69.31B | +22.06% | 0.00% |
| STG | -5.62% | $35.67M | +7.92% | 0.00% |
| TRMD | -5.62% | $2.31B | -24.74% | 25.24% |
ETF's related to ZYME
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -32.37% | $388.04M | 1.43% |
| VIXY | -18.45% | $195.31M | 0.85% |
| CTA | -16.98% | $350.27M | 0.78% |
| USDU | -15.20% | $201.97M | 0.5% |
| UUP | -13.81% | $309.25M | 0.77% |
| KMLM | -7.81% | $353.87M | 0.9% |
| FLTR | -7.40% | $1.79B | 0.14% |
| EQLS | -7.28% | $76.08M | 1% |
| AGZD | -6.85% | $142.76M | 0.23% |
| TAIL | -6.23% | $67.98M | 0.59% |
| BILZ | -4.94% | $563.02M | 0.14% |
| CLOI | -4.74% | $715.40M | 0.4% |
| SGOV | -3.76% | $27.53B | 0.09% |
| FLRN | -3.68% | $2.33B | 0.15% |
| KCCA | -3.29% | $220.51M | 0.87% |
| JUCY | -3.10% | $324.29M | 0.6% |
| PREF | -2.93% | $999.92M | 0.55% |
| DBA | -1.82% | $755.88M | 0.93% |
| BSCO | -1.78% | $2.35B | 0.1% |
| KRBN | -1.56% | $242.47M | 0.85% |
News
Finnhub
VANCOUVER, British Columbia, Nov. 21, 2024 -- Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard...
Finnhub
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response...
Yahoo
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancersVANCOUVER, British Columbia, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed
SeekingAlpha
PDUFA date for potential approval of Zanidatamab is set for Nov 29, developed in collaboration with Jazz Pharmaceuticals and BeiGene. Find out why ZYME stock is a Buy.
Yahoo
Zymeworks ( NASDAQ:ZYME ) Third Quarter 2024 Results Key Financial Results Revenue: US$16.0m (down 3.1% from 3Q 2023...
Yahoo
Today is shaping up negative for Zymeworks Inc. ( NASDAQ:ZYME ) shareholders, with the analysts delivering a...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.